Frohlich E D
South Med J. 1977 Jan;70(1):95-9. doi: 10.1097/00007611-197701000-00045.
Only recently approved for use in the treatment of hypertension in the US, the beta-adrenergic receptor blocking compound propranolol has been used elsewhere for this purpose since 1964. The exact mechanisms to explain why and how "beta-blocking drugs" reduce arterial pressure are not known with certainty, but possible explanations include: (1) "resetting" of the baroreceptors, (2) reduction of cardiac output, (3) adaptation of circulation ("autoregulation"), (4) inhibition of renin release, (5) central nervous system effects, (6) possible antihypertensive metabolites, and (7) other unknown mechanisms or a combination of known mechanisms. Propranolol alone has been demonstrated to be extremely effective in reducing arterial pressure. In addition, the combination of propranolol and vasodilator and diuretic drugs would be expected to reduce vascular resistance without reflexive cardiac stimulation and with prevention of sodium and fluid retention.
β-肾上腺素能受体阻断化合物普萘洛尔最近才在美国被批准用于治疗高血压,自1964年以来它已在其他地方用于此目的。确切解释“β受体阻滞剂”为何以及如何降低动脉压的机制尚不确定,但可能的解释包括:(1)压力感受器的“重置”;(2)心输出量减少;(3)循环适应(“自身调节”);(4)肾素释放受抑制;(5)中枢神经系统效应;(6)可能的降压代谢产物;以及(7)其他未知机制或已知机制的组合。已证明单独使用普萘洛尔在降低动脉压方面极为有效。此外,预计普萘洛尔与血管扩张剂和利尿剂联合使用可降低血管阻力,而不会引起反射性心脏刺激,并可防止钠和液体潴留。